Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
Financials
Financial year 2025
FARMACIE HENRI from Edegem, company number BE0467212772, closed financial year 2025 with a result of € -56,348 after tax. For that financial year FARMACIE HENRI recorded a gross margin of € 11,333 and equity of € 333,246. Compared with financial year 2024, the result moved from € -20,482 to € -56,348. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 8, 2026.
€ 333,246
▼ 14% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -56,348
▼ 175 % more loss than in 2024
Profit after tax over the fiscal year.
€ 182,474
▲ 13% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 313,246.
People and assets in 2025
0.5
▼ 1.8 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 41,329
▼ 59% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 1,990
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 268,997
▲ 136% vs 2024
€ 41,115 is repaid this year. At this pace the long-term loan is gone in ≈ 6 years.
€ 30,620
▲ 201% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 196
▼ 99% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 49,762 | € 100,153 | € 114,415 | € 11,333 | ▼ 90% |
| Profit after taxes | € -6,494 | € 9,567 | € -20,482 | € -56,348 | ▼ € 35,866 |
| Equity | € 400,509 | € 410,076 | € 389,594 | € 333,246 | ▼ 14% |
| Total debts | € 212,983 | € 189,844 | € 200,875 | € 302,399 | ▲ 51% |
| Cash | € 131,676 | € 145,320 | € 160,886 | € 182,474 | ▲ 13% |
| Land & buildings | € 168,883 | € 175,131 | € 166,449 | € 154,210 | ▼ 7% |
| Retained profit | € 380,509 | € 390,076 | € 369,594 | € 313,246 | ▼ 15% |
| Dividend | € 220,833 | € 0 | € 0 | € 0 | |
| Bank debt | € 185,056 | € 152,605 | € 113,979 | € 268,997 | ▲ 136% |
| Balance sheet total | € 613,491 | € 599,920 | € 590,469 | € 635,645 | ▲ 8% |
| Employees (FTE) | 0.5 | 0 | 2.3 | 0.5 | ▼ 1.8 |
Key figures of FARMACIE HENRI, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to FARMACIE HENRI?
What happened at FARMACIE HENRI in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 56,348. Source: NBB ↗
- SABU PHARMA BV became a director. NBB
- MARIJKE VAN ZUNDERT CONSULTING BV became a director. NBB
- New establishment in Edegem. KBO
- Start of the company according to the CBE. KBO
In short
From € 6,494 loss in 2022 to € 56,348 loss in 2025.
Paid € 617 in corporate taxes since 2022.
Best year ever: 2023, with € 9,567 profit.
On average € 49,700 of value added per employee in 2024.
A new publication or filing at FARMACIE HENRI? We notify you, reason included.
Follow FARMACIE HENRIDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of MARIJKE VAN ZUNDERT CONSULTING, ROEL FIEY MANAGEMENT, SABU PHARMA comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
FARMACIE HENRIBehind FARMACIE HENRI are MARIJKE VAN ZUNDERT CONSULTING BV and SABU PHARMA BV. The shares are held by MARIJKE VAN ZUNDERT CONSULTING (60%), ROEL FIEY MANAGEMENT (40%) and SABU PHARMA (40%).
Directors
According to the 2025 annual accounts
MARIJKE VAN ZUNDERT CONSULTING BV
Director · represented by Marijke Van Zundert
since 2021
Director · represented by Christ Sabushimike
since 2025
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Prins Boudewijnlaan 272
2650 Edegem
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0467.212.772
- VAT number
- BE 0467.212.772
- Registered office
- Prins Boudewijnlaan 272, 2650 Edegem
- Names & denominations
- FARMACIE HENRI
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 4 November 1999
- Peppol
- Active · Active since 4 Dec 2025
- Activities · NACE
Detailhandel in farmaceutische producten
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering